Hot Features
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell matu... Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company’s lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -1.71 | -22.6490066225 | 7.55 | 7.62 | 5.815 | 158371 | 6.82329761 | CS |
| 4 | -2.37 | -28.8672350792 | 8.21 | 9.325 | 5.815 | 164437 | 7.1705204 | CS |
| 12 | -2.35 | -28.6935286935 | 8.19 | 9.325 | 5.6 | 166973 | 6.80865534 | CS |
| 26 | -1.09 | -15.7287157287 | 6.93 | 9.33 | 5.6 | 186222 | 7.37935639 | CS |
| 52 | -3.71 | -38.8481675393 | 9.55 | 15.57 | 5.6 | 138670 | 8.10459118 | CS |
| 156 | 5.0335 | 624.116553007 | 0.8065 | 41.87 | 0.4711 | 232886 | 6.26865247 | CS |
| 260 | 5.0335 | 624.116553007 | 0.8065 | 41.87 | 0.4711 | 232886 | 6.26865247 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.